Official Title
Study of the Seroprevalence of SARS-CoV-2 in Hospital Staff in Strasbourg University Hospital, Strasbourg, France
Brief Summary

COVID-19 is a new emerging disease caused by infection with the SARS-CoV-2 coronavirus, with no specific therapeutic options. Since the end of February 2020, the Strasbourg University Hospital (HUS) had faced a sudden increase of patients with COVID-19 resulted from a SARS-CoV-2 superspreading event (religious meeting). Infected individuals went to regional hospitals, and this led to a cluster of infected healthcare workers at the Strasbourg University Hospitals from the first week of March. To date, several hundred Strasbourg hospital workers have presented a SARS-CoV-2 infection confirmed by the RT-PCR test from a nasopharyngeal sample. Most of them developed a mild form of COVID-19. It is important to understand how far the infection has spread in the hospital staff, and to which extent the individuals who have been infected develop antibodies against SARS-CoV-2.

Completed
SARS-CoV-2 Serological Status
SARS-CoV-2 Seroprevalence

Diagnostic Test: Blood sample for serological test

Serology tests:
By LFA-ICT: BIOSYNEX COVID-19 BSS reference SW40005, BIOSYNEX SWISS SA, Fribourg, Switzerland
ELISA: EDI™ Novel Coronavirus COVID-19 ELISA IgG Kit, Epitope Diagnostics, Inc., San Diego, USA
Confirmation test by seroneutralization tests developed at the Strasbourg Virology laboratory on whole virus (analyzes performed in a biosafety level 3 laboratory) and by the viral pseudoparticles system, will be performed.

Eligibility Criteria

Inclusion Criteria:

- Any person, male or female, over 18 years of age at the time of signing the consent

- Any person affiliated to a social health insurance scheme

- Any person able to understand the objectives and risks related to research and to give
an informed, dated and signed consent

- Any person who is part of HUS staff and working at HUS at the time of the pandemic,
including residents affiliated with HUS and assigned to general hospitals in the
region

- Any symptomatic person with a positive COVID result (PCR + group) or negative (PCR-
group) with a RT-PCR test carried out at least 10 days before inclusion, or any
person, for which no COVID PCR was performed (group " No PCR")

Exclusion Criteria:

- Person in exclusion period (determined by a previous or ongoing study),

- Inability to give clear information (person in an emergency, difficulty understanding
the subject, etc.)

- Person under safeguard of justice

- Person under guardianship or curatorship

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
France
Locations

Hôpitaux Universitaires de Strasbourg - Centre d'Investigation Clinique - Nouvel Hôpital Civil et Hautepierre
Strasbourg, France

University Hospital, Strasbourg, France
NCT Number
Keywords
Covid-19
SARS-CoV-2
Humoral Response
T-cell response